(EISAI) A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease

The PI of this project was: Sanjay Asthana, MD

This project was funded by: Eisai Inc.

The term of this project was: January 2018 to January 2021

The number of subjects scanned during this project was: 10